Literature DB >> 30900204

Relationship among obesity, insulin resistance, and hyperinsulinemia in the polycystic ovary syndrome.

Michael H Dahan1, Gerald Reaven2.   

Abstract

PURPOSE: To evaluate the relationship between obesity and insulin resistance among women with polycystic ovary syndrome (PCOS) using a gold standard test.
METHODS: A retrospective database analysis of 75 women with PCOS and 118 normal controls who underwent a modification of the insulin suppression test. The relationships between body mass index (BMI) and steady-state plasma glucose (SSPG) levels were investigated.
RESULTS: Mean SSPG score for PCOS subjects was statistically similar than that of the controls at all BMI groupings. Only when PCOS subjects reached a BMI of ≥30 kg/m2 that the PCOS subjects had higher mean SSPG score than the control subjects, although not significantly so (p = 0.07). The distribution of PCOS and control subjects in each SSPG quartile grouping was investigated. When comparing all PCOS and control subjects, PCOS subjects were more likely to be in the higher quartiles of SSPG score (p = 0.0001). However, when comparing the PCOS and control subjects, at each BMI grouping (<25, 25-29.9, and ≥30 kg/m2), there was no difference in the likelihood that a larger percent of subjects fell into a different quartile (p = 0.12, 0.69, 0.32, respectively).
CONCLUSIONS: PCOS subjects have increased magnitudes of insulin resistance when compared to ovulatory controls, when controlling for age, BMI, fasting glucose, and insulin levels. However, the magnitude of this insulin resistance in lean subjects is mild. Quantity of excess body fat, particularly subjects with a BMI of at least 30 kg/m2 is the primary predictor of insulin resistance of sufficient magnitude to put PCOS subjects at increased risk for metabolic abnormalities.

Entities:  

Keywords:  BMI; Insulin resistance; Insulin suppression test; Obesity; PCOS

Mesh:

Substances:

Year:  2019        PMID: 30900204      PMCID: PMC6557720          DOI: 10.1007/s12020-019-01899-9

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  8 in total

1.  The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.

Authors:  A Dunaif; J Mandeli; H Fluhr; A Dobrjansky
Journal:  J Clin Endocrinol Metab       Date:  1988-01       Impact factor: 5.958

2.  Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.

Authors:  A Dunaif; K R Segal; W Futterweit; A Dobrjansky
Journal:  Diabetes       Date:  1989-09       Impact factor: 9.461

Review 3.  Banting lecture 1988. Role of insulin resistance in human disease.

Authors:  G M Reaven
Journal:  Diabetes       Date:  1988-12       Impact factor: 9.461

4.  Insulin resistance in nonobese patients with polycystic ovary syndrome.

Authors:  S Toprak; A Yönem; B Cakir; S Güler; O Azal ; M Ozata; A Corakçi
Journal:  Horm Res       Date:  2001

5.  Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance.

Authors:  J Holte; T Bergh; C Berne; L Berglund; H Lithell
Journal:  J Clin Endocrinol Metab       Date:  1994-05       Impact factor: 5.958

Review 6.  Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus.

Authors:  Fernando Ovalle; Ricardo Azziz
Journal:  Fertil Steril       Date:  2002-06       Impact factor: 7.329

7.  Insulin sensitivity in women with polycystic ovary syndrome.

Authors:  Jana Vrbíková; David Cibula; Katerina Dvoráková; Sona Stanická; Gustav Sindelka; Martin Hill; Michael Fanta; Karel Vondra; Jan Skrha
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

8.  Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome.

Authors:  P Ovesen; J Moller; H J Ingerslev; J O Jørgensen; A Mengel; O Schmitz; K G Alberti; N Moller
Journal:  J Clin Endocrinol Metab       Date:  1993-12       Impact factor: 5.958

  8 in total
  6 in total

1.  Metabolic syndrome and the risk of cardiovascular complications in young patients with different phenotypes of polycystic ovary syndrome.

Authors:  Anna Krentowska; Agnieszka Łebkowska; Małgorzata Jacewicz-Święcka; Justyna Hryniewicka; Monika Leśniewska; Agnieszka Adamska; Irina Kowalska
Journal:  Endocrine       Date:  2021-01-13       Impact factor: 3.633

2.  Among high responders, is oocyte development potential different in Rotterdam consensus PCOS vs non-PCOS patients undergoing IVF?

Authors:  Veronique Bellemare; Keren Rotshenker-Olshinka; Laura Nicholls; Alyson Digby; Amrita Pooni; Einav Kadour-Peero; Weon-Young Son; Michael H Dahan
Journal:  J Assist Reprod Genet       Date:  2022-08-27       Impact factor: 3.357

3.  The impact of hyperandrogenism on the outcomes of ovulation induction using gonadotropin and intrauterine insemination in women with polycystic ovary syndrome.

Authors:  Vu Ngoc Anh Ho; Toan Duong Pham; Nam Thanh Nguyen; Hieu Le Trung Hoang; Tuong Manh Ho; Lan Ngoc Vuong
Journal:  Clin Exp Reprod Med       Date:  2022-05-27

Review 4.  Immunophenotypic Profiles in Polycystic Ovary Syndrome.

Authors:  Cong Hu; Bo Pang; Zhanchuan Ma; Huanfa Yi
Journal:  Mediators Inflamm       Date:  2020-03-19       Impact factor: 4.711

5.  Triglyceride-glucose index is associated with the risk of myocardial infarction: an 11-year prospective study in the Kailuan cohort.

Authors:  Xue Tian; Yingting Zuo; Shuohua Chen; Qian Liu; Boni Tao; Shouling Wu; Anxin Wang
Journal:  Cardiovasc Diabetol       Date:  2021-01-12       Impact factor: 9.951

6.  Pathogenesis of Reproductive and Metabolic PCOS Traits in a Mouse Model.

Authors:  Valentina Rodriguez Paris; Melissa C Edwards; Ali Aflatounian; Michael J Bertoldo; William L Ledger; David J Handelsman; Robert B Gilchrist; Kirsty A Walters
Journal:  J Endocr Soc       Date:  2021-04-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.